Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Estrogen-progestin use and breast cancer characteristics in lean and overweight postmenopausal women.

Tytuł:
Estrogen-progestin use and breast cancer characteristics in lean and overweight postmenopausal women.
Autorzy:
Kjartansdottir OJ; Department of Clinical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK.; Department of Internal Medicine, Landspitali University Hospital, Reykjavik, Iceland.; Icelandic Cancer Registry, Icelandic Cancer Society, Reykjavik, Iceland.
Sigurdardottir LG; Department of Education and Prevention, Icelandic Cancer Society, Reykjavik, Iceland.
Olafsdottir EJ; Icelandic Cancer Registry, Icelandic Cancer Society, Reykjavik, Iceland.
Jonasson JG; Department of Pathology, Landspitali University Hospital, Reykjavik, Iceland.; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Ursin G; Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway.; Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA.; Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.
Tryggvadottir L; Icelandic Cancer Registry, Icelandic Cancer Society, Reykjavik, Iceland. .; Faculty of Medicine, University of Iceland, Reykjavik, Iceland. .
Źródło:
Breast cancer research and treatment [Breast Cancer Res Treat] 2017 Jun; Vol. 163 (2), pp. 363-373. Date of Electronic Publication: 2017 Mar 09.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Publication: Dordrecht : Kluwer Academic
Original Publication: The Hague ; Boston : M. Nijhoff, c1981-
MeSH Terms:
Estrogen Replacement Therapy*
Breast Neoplasms/*epidemiology
Carcinoma, Ductal, Breast/*epidemiology
Carcinoma, Lobular/*epidemiology
Estrogens/*therapeutic use
Progestins/*therapeutic use
Breast Neoplasms/pathology ; Carcinoma, Ductal, Breast/pathology ; Carcinoma, Lobular/pathology ; Case-Control Studies ; Estrogens/pharmacology ; Female ; Humans ; Middle Aged ; Overweight/epidemiology ; Overweight/pathology ; Progestins/pharmacology ; Prospective Studies
Contributed Indexing:
Keywords: Body Mass Index; Breast cancer; Estrogen; Menopausal hormone therapy; Progesterone; Tumor characteristics
Substance Nomenclature:
0 (Estrogens)
0 (Progestins)
Entry Date(s):
Date Created: 20170311 Date Completed: 20180219 Latest Revision: 20180219
Update Code:
20240104
DOI:
10.1007/s10549-017-4171-2
PMID:
28281022
Czasopismo naukowe
Purpose: Breast cancer associated with estrogen-progestin (EP) therapy may have more favorable characteristics than cancer in never users, but results are conflicting. It is not well known either whether Body Mass Index (BMI) modifies this association. We investigated breast cancer characteristics in EP users for lean (BMI < 25 kg/m 2 ) and overweight women (BMI ≥ 25 kg/m 2 ).
Methods: The Icelandic Cancer Detection Clinic cohort, with information on breast cancer risk factors for 90% of Icelandic women, was linked with the population-based Icelandic Cancer Registry. A total of 781 women with invasive breast cancer diagnosed 51 years or older were matched with 7761 controls from the cohort. Conditional logistic regression was used for estimating adjusted odds ratios (OR) and 95% confidence intervals (CI) according to tumor characteristics, stratified by BMI. Polytomous logistic regression was applied in a case-only analysis for testing whether the risk associated with EP use differed according to tumor characteristics.
Results: Ever EP users had a twofold higher risk of breast cancer compared with never users (OR 2.05, 95% CI 1.71-2.45). In lean women, EP use was significantly less likely to be associated with grade 2 or 3 tumors than grade 1 tumors, contrary to overweight women for whom risk was increased irrespective of grade. EP use in overweight women was associated with a higher risk of lobular than ductal cancer (OR 2.75, 95% CI 1.29-5.87).
Conclusion: Among lean EP users, tumor characteristics were more favorable than among never users. This effect was not observed for overweight women.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies